Key result
Myocardial DYRK1A is inversely linked to LV mass regression, and its activation normalizes myofilamentary stiffness.
Why the study?
Does DYRK1A modulate myofilamentary stiffness and reverse remodeling in the context of aortic valve replacement?
Observational (n=34)
No
Does DYRK1A modulate myofilamentary stiffness and reverse remodeling in the context of aortic valve replacement?
DYRK1A emerges as a potential therapeutic target to treat myocardial stiffness-driven diastolic dysfunction following aortic valve replacement.
Answers are grounded in this paper and cite their sources.
DYRK1A may represent a target for residual stiffness after AVR; hypothesis-generating in animal models, clinical translation remains open.
mice and from AVS patients upon incubation with this kinase. Cardiomyocytes from mutant mice showed increased myofilamentary stiffness in response to stretch. Also, the raised myofilamentary stiffness of cardiomyocytes isolated from incomplete RR was normalised upon incubation with DYRK1A. Better myocardial bioenergetics may underscore a complete LVM regression. In turn, complement and immune-inflammatory pathways activation prime an incomplete response to AVR. DYRK1A emerges as a surrogate target to treat myocardial stiffness-driven diastolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Trindade et al. (2025) conducted an observational in Aortic valve stenosis (n=34). Aortic valve replacement vs. Incomplete reverse remodelling (iRR) vs Complete reverse remodelling (cRR) was evaluated on Correlation between DYRK1A and left ventricle mass (LVM) regression (r = -0.62). Myocardial phosphoproteomics revealed that DYRK1A is inversely correlated with left ventricle mass regression and its activation normalizes myofilamentary stiffness in incomplete reverse remodelling.
Synapse has enriched 10 related papers. Consider them for comparative context: